The biology of castration-resistant prostate cancer

Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer death in men in the United States.1 Although there are recently approved therapeutic options for men with advanced and metastatic disease, the unfortunate reality is that advanced prostate cancer is inevitably fatal. Hormonal androgen deprivation therapy (ADT)2 is the standard of care once a patient has recurrent disease following primary surgical or radiation therapy; however, the benefits from ADT are typically short lived.

Source: Current Problems in Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Fei Lian, Nitya V. Sharma, Josue D. Moran, Carlos S. Moreno Source Type: research